三力制药：与海南大学签署总额2亿元技术转让合同

Core Viewpoint - Sanli Pharmaceutical has signed a technology transfer contract with Hainan University for the acquisition of the compound HXW2324 and related patent application rights, aiming to enhance its innovative drug product portfolio and align with its long-term strategic goals [1] Group 1: Technology Transfer Agreement - The total transfer price for the invention patent rights or patent application rights is set at 200 million yuan, which includes a milestone payment of 20 million yuan (tax included) and a sales commission of 180 million yuan (tax included) [1] - The compound HXW2324 is a preclinical candidate for developing new treatments for Alzheimer's disease [1] Group 2: Company Background and Financials - Sanli Pharmaceutical's main business includes the research, production, and sales of pharmaceuticals, with key products such as throat spray for children, Qi Jiao Sheng Bai capsules, and others [1] - In the first three quarters of this year, the company achieved operating revenue of 1.038 billion yuan and a net profit attributable to shareholders of 81 million yuan [1]